Kodiak Sciences Inc. (KOD) Stock
1 member of Congress disclosed 2 trades in KOD since 2022: 1 purchase and 1 sale, most recently Christopher L. Jacobs (sale, Nov 8, 2022). 5 of the hedge funds AlphaScala tracks reported KOD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $8.23M. Company insiders reported 86 open-market buys and 8 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded Kodiak Sciences Inc. (KOD)?
Most recent: Christopher L. Jacobs (sale, Nov 8, 2022); records start Jul 18, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-11-08 | sale | $1k – $15k |
| Chris Jacobs R-NY · House | 2022-07-18 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all KOD political trades →Which hedge funds own KOD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 211K | $8.23M | -8% |
| Renaissance Technologies Jim Simons (founder) | 189K | $7.37M | -36% |
| Citadel Ken Griffin | 158K | $6.14M | -82% |
| Point72 Steve Cohen | 98K | $3.80M | -79% |
| Millennium Management Israel Englander | 31K | $1.21M | +118% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Kodiak Sciences Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 5, 26 | Baker Bros. Advisors Lp | Director | BUY | 4.7K | $463K |
| Nov 5, 26 | Baker Bros. Advisors Lp | Director | BUY | 81.7K | $8.1M |
| Nov 4, 26 | Baker Bros. Advisors Lp | Director | BUY | 8.7K | $861K |
| Nov 4, 26 | Baker Bros. Advisors Lp | Director | BUY | 151.9K | $15.0M |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 8.5K | $746K |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 1.7K | $150K |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 7.6K | $684K |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 5.1K | $464K |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 3.0K | $274K |
| Oct 21, 26 | Borgeson John A. | Chief Financial Officer | SELL | 2.0K | $185K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →AlphaScala analysis on KOD
Latest 1KOD price chart
Powered by TradingViewWhat does Kodiak Sciences Inc. do?
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-prevalence ophthalmic conditions that lead to vision loss, including wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, uveitis, and macular edema secondary to inflammation. Its proprietary Antibody Biopolymer Conjugate Drug platform enables multi-modal treatments through bio-inspired antibody biopolymer conjugates. Key pipeline candidates include tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer in Phase 3 studies for retinal vascular diseases; KSI-501, a bispecific anti-IL-6 and VEGF-trap for inflammatory retinal conditions; and KSI-101, targeting IL-6 and VEGF for patients with retinal fluid and inflammation. Kodiak Sciences Inc. operates as a retina-focused biotechnology firm advancing late-stage programs to address unmet needs in ophthalmology. Founded in 2009 and headquartered in Palo Alto, California, it remains committed to developing innovative biologic medicines for complex ocular diseases.